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Background: Atrial fibrillation (AF) activates the coagulation system, 
leading to hypercoagulation of the blood. The liver is a major source of 
prothrombotic molecules. 
Objectives: This study aimed to clarify whether cardiohepatic interactions 
are involved in AF-related hypercoagulation. 
Methods: We compared gene expression profiles of the human liver tissue 
between AF patients and controls. An AF model was created by rapid atrial 
pacing (RAP) at a frequency of 1200 bpm in anesthetized 10-week-old 
Sprague-Dawley rats. Livers, atria, and peripheral blood cells were 
collected and analyzed after 12 h of RAP. 
Results: DNA microarray analysis revealed marked changes in the gene 
expression profile of the human liver of AF patients. The extrinsic 
prothrombin activation pathway showed the most prominent change among 
354 BioCarta pathways. Twelve hours of RAP also markedly altered the 
gene expression profile of rat liver. RAP markedly augmented the hepatic 
mRNA expressions of fibrinogen chains, prothrombin, coagulation factor X, 
and antithrombin III. The augmented fibrinogen production by RAP was 
accompanied by increased IL-6 mRNA expression in peripheral blood cells, 
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enhanced MCP-1 expression in the liver, infiltrated CD11b positive 
mononuclear cells into the liver, and enhanced STAT3 phosphorylation in 
hepatocytes nuclei. STAT3 phosphorylation and increased fibrinogen and 
coagulation factor X production by RAP were suppressed by pretreatment 
with IL-6 neutralizing antibody. 
Conclusion: Rapid atrial excitation mimicking paroxysmal AF remotely 
altered the hepatic gene expression of prothrombotic molecules. Increased 
fibrinogen expression in the liver by RAP was mediated by activation of 
the IL-6/STAT3 signaling pathway in the peripheral blood and liver. 
 





Atrial fibrillation (AF), the most common type of sustained arrhythmia in 
adults, is associated with a five-fold increase in ischemic stroke 
incidences.
1,2
 Most strokes in AF patients are believed to be cardioembolic 
caused by the embolism of left atrial thrombi.
3
 As shown by the 
well-known Virchow’s triad, thrombus formation in the left atrium (LA) 
can result from decreased blood flow, increased endocardial dysfunction in 
the LA, and enhanced blood coagulability.
4,5
 Spontaneous echo contrast 
formation in the LA is promoted by decreased blood flow velocity and is 
strongly associated with left atrial appendage thrombus and cardioembolic 
events.
6
 Previous studies have also determined that AF-associated 
endocardial dysfunction is characterized by an increase in von Willebrand 
factor, nitric oxide (NO), and plasminogen activator inhibitor-1 expression 
and a decrease in NO synthase expression in the LA.
7,8
 Even short-term 
rapid atrial pacing (RAP) for 8 h induces a marked decrease in tissue factor 
pathway inhibitor and thrombomodulin expression in the atrial 
endocardium of rats.
9
 However, the mechanism of AF-induced 
hypercoagulation of the blood, connected with the third element of 
Virchow’s triad, is poorly understood. Because the liver is an essential 
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organ synthesizing many coagulation factors and other prothrombic 
molecules, we hypothesized that a cardiohepatic interaction is involved in 
AF. Here we examined whether short-term rapid atrial excitation affects 
gene expression remotely in the liver. 
 
Method 
Expanded methods can be found in the Online Supplemental Material. 
 
Rapid Atrial Pacing Model 
This study was conducted in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of 
Health using Sprague-Dawley rats, 8–12 weeks of age. It was approved by 
the Institutional Animal Use and Care Committee of Kanazawa University. 
An atrial tachycardia rat model was prepared as previously reported.
9,10
 
Right atrial stimulation at a frequency of 1200 bpm was performed with 
2-ms rectangular pulses using a programmable stimulator. Sham-surgery 
rats underwent an identical procedure without electrical stimulation. The 




Human liver tissue 
We screened 465 consecutive patients with non-alcoholic steatohepatitis 
who underwent liver biopsy from 2003 to 2013 and identified 3 patients 
with AF without structural heart disease. Three patients who were in sinus 
rhythm and matched for age, sex, and hepatic histopathological stage 
(Brunt’s pathologic criteria) served as a control group (Supplemental Table 
1). There was no statistical difference between the two groups in left atrial 
diameter. Informed consent was obtained from all patients before liver 
biopsy. The experimental protocol was approved by the Human Genome, 
Gene Analysis Research Ethics Committee of Kanazawa University 
(Approval No. 2014-002), and the study was conducted in accordance with 
the Declaration of Helsinki. 
 
Microarray Experiments, Quantitative Real-Time Polymerase Chain 
Reactions, Western Blot and Histological Analyses 
We performed microarray experiments using RNA from the liver tissues of 
humans and rats. Quantitative real-time polymerase chain reaction 
(RT-PCR) was performed using RNA from the liver, LA, spleen tissues 
and peripheral blood cells of rats. Western blot, immunohistochemical 
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staining and immunofluorescent staining were performed using liver tissues 
of rats. The detailed methods are shown in Online Supplementary Methods.  
 
Administration of IL-6 Neutralizing Antibody  
IL-6 neutralizing antibody (5 μg/400 kg BW) was intraperitoneally 
administered 1 day before and immediately subsequent to RAP onset. 
 
Statistical Analysis 
Continuous variables are presented as mean ± SEM for each group unless 
stated otherwise and were analyzed by ANOVA with Bonferroni post hoc 
testing for multiple comparisons and unpaired t-test for two-group 
comparisons. Categorical variables were compared using the chi-square test. 
Significance was set at P < .05. 
 
Results 
Gene Expression Profiles of the Human Liver in AF 
DNA microarray revealed marked changes in the gene expression profile of 
the human liver of AF patients. Of 54,675 human genes in the array, 4322 
filtered genes demonstrated clear clusters for AF or control (Supplemental 
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Figure 1). Table 1 displays significantly overrepresented BioCarta 
pathways in the liver of AF patients. The expression of genes related to 
coagulation, immunity, apoptosis, and hypoxia was significantly altered in 
AF. Notably, the extrinsic prothrombin activation pathway, including 
fibrinogen, showed the most prominent change among 354 BioCarta 
Pathways (Table 1). 
 
Characteristics of Experimental Rats 
At the time of euthanasia, ECG confirmed an atrial paced rhythm in each 
experimental animal. Arterial blood pressure was not different between 
12-h RAP and sham groups (Supplemental Figure 2A). Atrial pacing of 
1200 bpm brought the ventricular response from 2:1 to 3:1. Accordingly, 
the mean ventricular rates of the RAP model demonstrated a slightly higher 
trend but no statistical difference than the sham model (Supplemental 
Figure 2B). Additionally, there was no statistical difference between the 
groups in liver weight/body weight, arterial blood-gas parameters, or serum 





Gene Expression Profiles in Rat Liver after 12 h of RAP 
DNA microarray analysis revealed marked changes in the gene expression 
profile of rat liver after 12 h of RAP. Hierarchical clustering with 3737 
filtered genes demonstrated clear clusters for the RAP or sham groups 
(Figure 1). 
Quantitative RT-PCR showed that mRNA expression of fibrinogen α, β, 
and γ chains significantly increased in the liver after 12 h of RAP (2.01 fold, 
P = .0007; 1.34 fold, P = .0066; and 1.90 fold, P = .0032, respectively; n = 
5 (Figure 2A). Western blot analysis confirmed significantly increased 
fibrinogen immunoreactive proteins in the liver after 12 h of RAP (2.84 
fold; P = .0125; n = 5) (Figure 2B). Additionally, 12 h of RAP enhanced 
the mRNA expression of prothrombin, coagulation factor X, and ATIII in 
the liver (2.36 fold, P = .0240; 1.27 fold, P = .0206; and 2.02 fold, P 
= .0263, respectively; n = 5) (Figure 2C). Western blot analysis also 
showed significantly increased prothrombin, coagulation factor X, and 
ATIII immunoreactive proteins in the liver after 12 h of RAP (2.48 fold, P 
= .0098; 1.93 fold, P = .0451; 1.35 fold, P = .0348, respectively; n = 5) 
(Figure 2D). The serum levels of fibrinogen, prothrombin, coagulation 
factor X and ATIII did not change significantly up to 12 h of RAP 
10 
 
(Supplement Table 2). 
 
Upstream Regulators of Fibrinogen Expression 
To elucidate the mechanism of enhanced hepatic fibrinogen production 
with RAP, we quantified fibrinogen gene expression regulators in the LA, 
spleen and peripheral blood cells. IL-6 and TNF-α mRNA expression was 
upregulated in peripheral blood cells after 12 h of RAP (1.67 fold, P 
= .0444; 1.82 fold, P = .0288, respectively; n = 5) (Figure 3A) but not in 
the LA (Figure 3B) and the spleen (Supplemental Figure 3). IL-1β mRNA 
expression was unchanged in the LA, spleen and peripheral blood cells 
after 12-h RAP. 
 
Infiltration of Monocytes/Macrophages with Activation of the 
IL-6/STAT3 Signaling Pathway in the Liver 
MCP-1 mRNA expression was upregulated in the liver after 12 h of RAP 
(2.60 fold; P = .0015; n = 5) but not in the LA (Figure 4A) and the spleen 
(Supplemental Figure 3). Western blot analysis showed that RAP 
significantly increased MCP-1 immunoreactive proteins in the liver (1.68 
fold; P = .0462; n = 5) (Figure 4B). Immunohistochemical analysis 
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identified many CD11b-positive cells in the liver after 12 h of RAP (Figure 
4C). Western blot analysis confirmed significantly increased CD11b 
immunoreactive protein in the liver of RAP rats compared with sham (1.27 
fold, P = .0048, n = 5, Figure 4D). The immunofluorescence 
double-labeling experiments showed the coexpression of IL-6 and CD11b 
(Figure 4E), suggesting infiltration of activated monocytes/macrophages 
into the liver. The RAP-induced increase in monocytes expressing IL-6 was 
accompanied by enhanced STAT3 phosphorylation (2.14 fold; P = .0023) 
(Figure 4D) in the liver. Phosphorylated STAT3 protein was prominent in 
the nuclei of hepatocytes with RAP (Figure 4C). 
 
Effects of IL-6 Neutralizing Antibody on RAP-induced STAT3 
Phosphorylation and Fibrinogen Production 
To further study the role of IL-6 in RAP-induced fibrinogen production in 
the liver, we administered IL-6 neutralizing antibody to the rats. IL-6 
neutralizing antibody mildly attenuated the RAP-induced increases in 
mRNA expression of MCP-1 (Figure 5A), MCP-1 immunoreactive proteins 
(Figure 5B) and CD11b (Figure 5C) in the liver, but the differences were 
not statistically significant. STAT3 phosphorylation promoted by RAP was 
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significantly suppressed by pretreatment with IL-6 neutralizing antibody 
(0.53 fold vs 12-h RAP; P = .0012; n = 5) (Figure 5D). Accordingly, IL-6 
neutralizing antibody significantly attenuated the RAP-induced increases in 
mRNA expression of fibrinogen α and γ chains (0.43 fold vs 12-h RAP, P 
< .0001; 0.61 fold vs 12-h RAP, P = .0087, respectively; n = 5) (Figure 6A) 
and fibrinogen immunoreactive proteins (0.54 fold vs 12-h RAP; P 
< .0001; n = 5) (Figure 6B). IL-6 neutralizing antibody also significantly 
prevented the RAP-induced increases in mRNA expression of coagulation 
factor X (0.65 fold vs 12-h RAP, P =.0001; n = 5) (Figure 6C) and 
coagulation factor X immunoreactive proteins (0.47 fold vs 12-h RAP; 
P=.0146; n = 5) (Figure 6D). On the other hands, mRNA/protein 
expression of prothrombin and ATIII were not suppressed by pretreatment 
with IL-6 neutralizing antibody (Figure 6C and 6D). 
 
Discussion 
The major findings of this study are as follows: 1) AF markedly affected 
the gene expression profile of the human liver. The extrinsic prothrombin 
activation pathway showed the most prominent change among the BioCarta 
pathways. 2) Twelve hours of RAP mimicking AF markedly altered the 
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gene expression profile of the rat liver. Hepatic mRNA expression of 
prothrombic molecules, including fibrinogen chains, prothrombin, 
coagulation factor X, and ATIII, was augmented by short-term RAP. 3) 
The augmented fibrinogen production with RAP was accompanied by 
increased IL-6 mRNA expression in peripheral blood cells, enhanced 
MCP-1 expression in the liver, infiltrated CD11b positive mononuclear 
cells into the liver, and enhanced STAT3 phosphorylation in the nuclei of 
hepatocytes. 4) STAT3 phosphorylation and increased fibrinogen 
production in the liver by RAP were suppressed by pretreatment with IL-6 
neutralizing antibody. 
Thrombus formation in AF is known to result from a decrease in blood 
flow,
6
 impairment of the atrial endocardial function,
7-9
 and 
hypercoagulability of the blood, as shown in Virchow’s triad.4,5 
Accordingly, studies have reported hypercoagulability of blood with 
increased serum TAT in AF patients.
11,12
 Notably, serum fibrinogen and 
D-dimer levels are elevated in patients just after 12 h following the AF 
onset.
13,14
 However, the mechanism underlying enhanced blood 
coagulability associated with AF has not been fully elucidated till date. 
The liver is an essential organ that synthesizes many bioactive proteins, 
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including acute-phase inflammatory proteins (e.g., C-reactive protein) and 
coagulation factors. Animal models of acute kidney injury have shown that 
acute impairment of renal function affects hepatic inflammatory 
responses;
15,16
 thus, renal-hepatic crosstalk is likely present in acute kidney 
disease. Acute coronary syndrome is accompanied by systemic 
manifestations such as proinflammatory responses and coagulation system 
activation;
17
 therefore, cardiohepatic interaction is implicated in acute 
coronary syndrome. In a previous study by our group, marked changes in 
hepatic gene expression were observed in the mouse model of myocardial 
infarction and ischemia/reperfusion.
18
 However, AF-related changes in 
hepatic gene expression have not been addressed. To the best of our 
knowledge, our data provides the first evidence that AF remotely and 
markedly alters liver gene expression profiles, primarily those involved in 
the extrinsic coagulation pathway. 
 The IL-6-dependent STAT3 phosphorylation has recently been shown to 
be involved in regulating acute phase proteins, including fibrinogen.
19
 IL-6 
is mainly secreted by mononuclear cells such as monocytes and 
macrophages. Based on previous reports demonstrating that AF causes 
atrial endocardial dysfunction
7-9
, we initially hypothesized that the LA may 
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be involved in RAP-induced IL-6 production. However, in our RAP model, 
IL-6 mRNA expression was increased in peripheral blood cells but not in 
the LA. In fact, in human paroxysmal (and persistent) non-valvular 
hypertensive AF patients, IL-6 and TNF-α mRNA in monocytes were 
upregulated in accordance with our results.
20
 Acute-onset AF activates 
platelets within minutes to initiate platelet-mononuclear cell interaction.
21
 
This phenomenon may underlie peripheral mononuclear cell production of 
IL-6 and TNF-α. 
In the animal model of subacute myocardial infarction, mononuclear 
cells were recruited in the peripheral blood, and the highest number of 
exited mononuclear cells was found in the liver, followed by the draining 
lymph nodes and the spleen.
22
 Mononuclear cell migration into the liver is 
mainly facilitated by profound secretion of MCP-1 by non-parenchymal 
liver cells such as Kupffer cells, liver stellate cells, and damaged 
hepatocytes.
23-25
 Our data demonstrate RAP-enhanced MCP-1 expression, 
CD11b positive mononuclear cells in the liver, and STAT3 
phosphorylation in the nuclei of hepatocytes. Moreover, the RAP-induced 
STAT3 phosphorylation and increased fibrinogen production were 
suppressed by pretreatment with IL-6 neutralizing antibody. These findings 
16 
 
suggest that the activated peripheral blood monocytes infiltrate the liver 
and secrete IL-6 to promote fibrinogen production via STAT3 
phosphorylation in hepatocytes. On the other hand, in LA and spleen, the 
increases of MCP-1 and IL-6 expression were not observed. These findings 
might imply that activated mononuclear cells affect predominantly to the 
liver in the present animal model. 
Coagulation Factor X plays a central role in the coagulation cascade. 
Factor X is synthesized in the liver, and its promoter activity is 
significantly increased by expression of GATA-4.
26
 A previous study 
reported that IL-6 stimulation increased the binding of GATA-4 to the 
HAMP promoter.
27
 Our data demonstrated that RAP-induced coagulation 
factor X production was suppressed by IL-6 neutralizing antibody, 
suggesting the involvement of IL-6 in the production of factor X, as well as 
fibrinogen in AF. 
Interestingly, several studies have indicated that serum IL-6 levels are 
associated with AF occurrence.
28-30
 Additionally, in a large cohort of 
anticoagulated permanent/paroxysmal AF patients, serum IL-6 level was an 
independent predictor of cardiovascular events and death, and the addition 
of IL-6 resulted in improved prediction performance of the 
17 
 
CHA2DS2-VASc clinical risk stratification schemes.
31
 These observations 




In the analysis of human liver, we only included small number of 
patients with liver disease due to ethical reason. Although the patients’ 
characteristics including histological fibrosis stage of the liver were not 
different between AF and control groups, the interpretation of the 
transcriptomics might be confounded by the presence of steatohepatitis and 
other comorbidities. 
In the rat with short-term RAP, the expressions of IL-6, TNF-α and 
IL-1β was enhanced in the liver but not in the LA and spleen. However, it 
is not rationale to think that the liver is the only organ affected by AF, 
because RAP augmented IL-6 mRNA expression in the peripheral 
mononuclear cells, suggesting the systemic inflammatory effects of AF. In 
fact, the recent study reported that the number of monocytes in the spleen 
was reduced and that of macrophages infiltrating the LA was increased on 





In this study, the mRNA/protein levels of fibrinogen, prothrombin, 
coagulation factor X and ATIII in the liver were increased after 12-h RAP, 
however, they were unchanged in the peripheral blood, possibly due to the 
short duration (12 h) of RAP. In the rats suffering from turpentine-induced 
inflammation, the peak of fibrinogen level was observed at 24 h in the liver 
and 40 h in plasma.
33
 The duration of RAP in this study was up to 12 h due 
to difficulty of maintaining the hemodynamics of rats for more than 12 h 
under the anesthesia. 
Although we determined that the IL-6/STAT3 signaling pathway is 
involved in RAP-induced hepatic fibrinogen production, we could not 
exclude the existence of other mediators, such as hemodynamic stress 
and/or autonomic nerve activity. Liver congestion may be involved in the 
changes in hepatic gene expression after 12 h of RAP. However, in this 
study, there was no statistical difference in arterial blood pressure, heart 
rate, liver weight/body weight, arterial blood gas parameters, or serum liver 







Short-term rapid atrial excitation mimicking paroxysmal AF markedly 
altered the hepatic gene expression profile and promoted the production of 
prothrombotic molecules in the rat liver. Augmented hepatic fibrinogen 
expression by RAP was partially mediated by the activation of the 
IL-6/STAT3 signaling pathway in the peripheral blood and liver. 
 
Acknowledgments 
We thank Toshinari Takamura, Yumie Takeshita, Masao Honda, Tatsuya 
Yamashita, Kuniaki Arai and Hajime Sunagozaka for human sample 
collection and Ayano Nomura and Mikiko Nakamura for the excellent 




1. Flegel KM, Shipley MJ, Rose G. Risk of stroke in nonrheumatic atrial 
fibrillation. Lancet 1987;1:526-529. 
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent 
risk factor for stroke: Framingham Study. Stroke 1991;22:983-988. 
3. Manning WJ, Siverman DI, Waksmonski CA, Oettgen P, Douglas PS. 
Prevalence of residual left atrial thrombi among patients with acute 
thromboembolism and newly recognized atrial fibrillation. Arch Intern 
Med 1995;55:2193-2198. 
4. Virchow RR. Cellular pathology. London: Churchill; 1860. 
5. Yamashita T. Molecular basis of thromboembolism in association with 
atrial fibrillation. Circ J 2007;71 Suppl A:A40-44. 
6. Fatkin D, Kelly RP, Feneley MP. Relations between left atrial 
appendage blood flow velocity, spontaneous echo cardiographic 
contrast and thromboembolic risk in vivo. J Am Coll Cardiol 
1994;23:961-969. 
7. Fukuchi M, Watanabe J, Kumagai K, et al. Increased von Willebrand 
factor in the endocardium as a local predisposing factor for 




8. Cai H, Li Zongming, Goette A, Mera F, Honeycutt C, Feterik K, 
Wilcox JN, Dudley SC, Harrison D. Down-regulation of endocardial 
nitric oxide synthase expression and nitric oxide production in atrial 
fibrillation. Potential mechanisms for atrial thrombosis and stroke. 
Circulation 2002;106:2854-2858. 
9. Yamashita T, Sekiguchi A, Iwasaki Y, Sagara K, Hatano S, Iinuma H, 
Aizawa T, Fu LT. Thrombomodulin and tissue factor pathway inhibitor 
in endocardium of rapidly paced rat atria. Circulation 
2003;108:2450-2452. 
10. Yamashita T, Murakawa Y, Hayami N, Fukui E, Kasaoka Y, Inoue M, 
Omata M. Short-term effects of rapid pacing on mRNA level of 
voltage-dependent K+ channels in rat atrium: electrical remodeling in 
paroxysmal atrial tachycardia. Circulation 2000;101:2007-2014. 
11. Soncini M, Casazza F, Mattioli R, Bonfardeci C, Motta A, 
Cimminiello C. Hypercoagulability and chronic atrial fibrillation: the 
role of markers of thrombin generation. Minerva Med 
1997;88:501-505. 
12. Topcuoglu MA, Haydari D, Ozturk S, Ozcebe OI, Saribas O. Plasma 
22 
 
levels of coagulation and fibrinolysis markers in acute ischemic stroke 
patients with lone atrial fibrillation. Neurol Sci 2000;21:235-240. 
13. Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin 
D-dimer levels in paroxysmal atrial fibrillation: evidence for 
intermediate elevated levels of intravascular thrombogenesis. Am 
Heart J 1996;131:724-730. 
14. Wang TL, Hung CR, Chang H. Evolution of plasma D-dimer and 
fibrinogen in witnessed onset of paroxysmal atrial fibrillation. 
Cardiology 2004;102:115-118. 
15. Park SW, Chen SW, Kim M, Brown KM, Kolls JK, D’Agati VD, Lee 
HT. Cytokines induce small intestine and liver injury after renal 
ischemia or nephrectomy. Lab Invest 2011;91:63-84. 
16. Fadillioglu E, Kurcer Z, Parlakpinar H, Iraz M, Gursul C. Melatonin 
treatment against remote organ injury induced by renal ischemia 
reperfusion injury in diabetes mellitus. Arch Parm Res 
2008;31:705-712. 
17. Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Tsoufis C, 
Marinou K, Charakida M, Stefanadi E, Vavuranakis M, Latsios G, 
Stefanadis C. Differences in inflammatory and thrombotic markers 
23 
 
between unstable angina and acute myocardial infarction. Int J Cardiol 
2007;115:203-207. 
18. Ootsuji H, Honda M, Kaneko S, Usui S, Okajima M, Sakai Y, 
Takamura T, Horimoto K, Takamura M. Altered hepatic gene 
expression profiles associated with myocardial ischemia. Circ 
Cardiovasc Genet 2010;3:68-77. 
19. Amrani DL. Regulation of fibrinogen biosynthesis: glucocorticoid 
and interleukin-6 control. Blood Coagul Fibrinolysis 1990;1:443-446. 
20. Chen X, Bing Z, He J, Jiang L, Luo X, Su Y, Kan B, Huang D, Wei Y. 
Downregulation of peroxisome proliferator-activated receptor-gamma 
expression in hypertensive atrial fibrillation. Clin Cardiol 
2009;32:337-345. 
21. Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, 
Murohara T. Platelet activation and induction of tissue factor in acute 
and chronic atrial fibrillation: involvement of mononuclear cell-platelet 
interaction. Thromb Res 2011;128:e113-118. 
22. Leuschner F, Rauch PJ, Ueno T, et al. Rapid monocyte kinetics in 
acute myocardial infarction are sustained by extramedullary 
monocytopoiesis. J Exp Med 2012;209:123-137. 
24 
 
23. Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux 
F, Weber C, Merad M, Luedde T, Trautwein C, Tacke F. Hepatic 
recruitment of the inflammatory Gr1+ monocyte subset upon liver 
injury promotes hepatic fibrosis. Hepatology 2009;50:261-274. 
24. Dambach DM, Watson LM, Gray KR, Durham SK, Laskin DL. Role 
of CCR2 in macrophage migration into the liver during 
acetaminophen-induced hepatotoxicity in the mouse. Hepatology 
2002;35:1093-1103. 
25. Marra F, DeFranco R, Grappone C, Milani S, Pastacaldi S, Pinzani M, 
Romanelli RG, Laffi G, Gentilini P. Increased expression of monocyte 
chemotactic protein-1 during active hepatic fibrogenesis: correlation 
with monocyte infiltration. Am J Pathol 1998;152:423-430. 
26. Hung HL, Pollak ES, Kudaravalli RD, Arruda V, Chu K, High KA. 
Regulation of human coagulation factor X gene expression by GATA-4 
and the Sp family of transcription factors. Blood 2001;97:946-951. 
27. Bagu ET, Santos MM. Friend of GATA suppreses the GATA-induced 
transcription of hepcidin in hepatocytes through a GATA-regulatory 
element in the HAMP promoter. J Mol Endocrinol 2011;47:299-313. 
28. Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, 
25 
 
Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary 
artery disease: data from the Heart and Soul Study. Am Heart J 
2008;155:303-309. 
29. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, 
Andreadou IT, Venetsanou KS, Iliodromitis EK, Kremastinos DT. The 
predictive value of inflammatory and oxidative markers following the 
successful cardioversion of persistent lone atrial fibrillation. Int J 
Cardiol 2009;135:361-369. 
30. Laireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, 
Uzdavinys G, Norkunas G, Kalinauskas G, Sirvydis V, Aidietis A, Lip 
GY. Characterisation and validity of inflammatory biomarkers in the 
prediction of post-operative atrial fibrillation in coronary artery disease 
patients. Thromb Haemost 2010;104:122-127. 
31. Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, 
Manzano-Fernández S, Casas T, Valdés M, Vicente V, Lip GY. High 
sensitivity cardiac troponin T and interleukin-6 predict adverse 
cardiovascular events and mortality in anticoagulated patients with 
atrial fibrillation. J Thromb Haemost 2012;10:1500-1507. 
32. Kondo H, Takahashi N, Gotoh K, Fukui A, Saito S, Aoki K, Kume O, 
26 
 
Shinohara T, Teshima Y, Saikawa T. Splenectomy exacerbates atrial 
inflammatory fibrosis and vulnerability to atrial fibrillation induced by 
pressure overload in rats: Possible role of spleen-derived interleukin-10. 
Heart Rhythm 2016;13:241-250.  
33. Courtoy PJ, Lombert C, Feldman G, Mogulievsky N, Rogier E. 
Synchronous increase of four acute phase proteins synthesized by the 
same hepatocytes during the inflammatory reaction: a combined 








 Gene expression profile in rat liver. Hierarchical clustering analysis and 
heat map depicting 3737 filtered genes (fold change ≥ 1.2) in rat liver for 
the 12-h rapid atrial pacing (RAP) and sham groups. (n = 4)  
Figure 2. 
 The effect of rapid atrial pacing (RAP) on expressions of coagulation 
factors in the rat liver. The effect of RAP on mRNA expression of 
fibrinogen chains (A); protein expression of fibrinogen (B); mRNA 
expression of prothrombin, coagulation factor X, and antithrombin III 
(ATIII) (C) and protein expression of prothrombin, coagulation factor X, 
and ATIII (D) in the liver. Both n = 5. *P < .05; **P < .01; ***P < .001 vs 
sham. GAPDH = Glyceraldehyde 3-phosphate dehydrogenase. 
Figure 3. 
 Upstream regulators of fibrinogen expression. The effect of rapid atrial 
pacing (RAP) on mRNA expression of interleukin (IL)-6, tumor necrosis 
factor (TNF)-α, and IL-1β in the left atrium (LA) (A) and peripheral blood 
cells (PBCs) (B). Both n = 5. *P < .05 vs sham. GAPDH = Glyceraldehyde 




 Infiltration of monocytes/macrophages with the activation of the 
interleukin (IL)-6/ signal transducer and activator of transcription (STAT) 3 
signaling pathway in the liver. A: The effect of rapid atrial pacing (RAP) on 
mRNA expression of monocyte chemoattractant protein (MCP)-1 in the 
liver and left atrium (LA). Both n = 5. *P < .05 vs sham. B: Western blot 
analysis of liver tissue for MCP-1. Both n = 5. *P < .05 vs sham. C: 
Immunohistochemical analysis for IL-6, cluster of differentiation (CD) 11b, 
and phopho-STAT3 (pSTAT3) in the liver. After 12 h of RAP, 
immunostaining indicative of IL-6 and CD11b was abundant in the liver 
(brown color). Also, pSTAT3 protein was prominent in the nuclei of 
hepatocytes after RAP (brown color). D: Western blot analysis of liver 
tissue for CD11b and STAT3 phosphorylation. Both n = 5. *P < .05 vs 
sham. **P < .01 vs sham. E: The immunofluorescence double-labeling 
experiments revealed coexpression of IL-6 (green) and CD11b (red) in the 
liver. GAPDH = Glyceraldehyde 3-phosphate dehydrogenase. 
Figure 5. 
 The effects of interleukin (IL) -6 neutralizing antibody (NA) on rapid 
atrial pacing (RAP) -induced monocytes/macrophages infiltration and 
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signal transducer and activator of transcription (STAT) 3 phosphorylation. 
A: mRNA expression of monocyte chemoattractant protein (MCP)-1 in the 
liver. B: Protein expression of MCP-1 in the liver. C: Western blot analysis 
of liver tissue for cluster of differentiation (CD) 11b. D: Western blot 
analysis of STAT3 phosphorylation. Both n = 5. *P < .05; **P < .01 vs 
sham;
††
P < .01 vs 12-h RAP group. GAPDH = Glyceraldehyde 
3-phosphate dehydrogenase. 
Figure 6. 
 The effects of interleukin (IL) -6 neutralizing antibody (NA) on rapid 
atrial pacing (RAP) -induced fibrinogen production and other coagulation 
molecules. A: mRNA expression of fibrinogen chains. B: Protein 
expression of fibrinogen. C: mRNA expression of prothrombin, coagulation 
factor X and antithrombin III (ATIII). D: Protein expression of prothrombin, 
coagulation factor X and ATIII. Both n = 5. *P < .05; **P < .01; ***P 
< .001 vs sham; 
†
P < .05; 
††
P < .01; 
†††
P < .001; 
††††
P < .0001 vs 12-h RAP 




Table 1. Significantly overrepresented BioCarta pathways in the liver 
of AF patients 
Gene and Frequent Pathway LS permutation 
p-value 
Extrinsic prothrombin activation pathway 0.00001 
Overview of telomerase protein component gene hTert 
Transcriptional regulation 
0.00001 
Complement pathway 0.00016 
p53 signaling pathway 0.00020 
Hypoxia and p53 in the cardiovascular system 0.00027 
CTCF: first multivalent nuclear factor 0.00040 
Estrogen-responsive protein Efp controls cell cycle 
and breast tumors growth 
0.00062 
Acute myocardial infarction 0.00068 
Apoptotic signaling in response to DNA damage 0.00088 
Lectin-induced complement pathway 0.00098 
Downregulated MTA-3 in ER-negative breast tumors 0.00173 





IL4 signaling pathway 0.00254 
Basic mechanism of action of PPARa, PPARb(d), and 
PPARg and effects on gene expression 
0.00342 
Activation of cAMP-dependent protein kinase, PKA 0.00364 
Regulation of elF4e and p70 S6 kinase 0.00373 
Signaling pathway from G-protein families 0.00407 
32 
 
Table 2. Characteristics of Experimental Animals 
 Sham 
(n = 5) 
4-h RAP 
(n = 5) 
8-h RAP 
(n = 5) 
12-h RAP 
(n = 5) 










 3.90 ± 0.06 3.93 ± 0.21 4.21 ± 0.11 3.89 ± 0.25 
Arterial blood gas parameters 








pCO2, mmHg 53.4 ± 2.7 41.8 ± 3.5 45.3 ± 2.1 44.1 ± 6.0 
pO2, mmHg 73.1 ± 4.2 96.9 ± 8.4 84.3 ± 10.6 82.2 ± 7.7 
HCO3, 
mmol/L 
27.0 ± 1.1 24.4 ± 1.0 26.7 ± 0.9 24.4 ± 2.8 
BE 0.44 ± 0.8 −0.04 ± 
0.56 
1.74 ± 0.77 −0.84 ± 
2.37 
Hb, g/dL 14.1 ± 0.6 14.4 ± 0.7 14.8 ± 0.6 14.4 ± 1.3 
Lactate, 
mmol/L 




Values are presented as mean ± SEM. No statistically significant 
differences in these parameters were observed between the groups. ALP = 
alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; BE = base excess; BW = body weight; Hb = hemoglobin; 
HCO3 = bicarbonate; LW = liver weight; pCO2, = partial pressure of carbon 
dioxide; pO2, = partial pressure of oxygen. 
 
Serum liver enzymes 
AST, U/L 72.2 ± 7.3 71.0 ± 7.4 71.4 ± 4.1 71.2 ± 3.3 
ALT, U/L 34.4 ± 5.0 31.6 ± 1.6 35.6 ± 1.8 35.8 ± 2.2 
ALP, U/L 497.6 ± 
28.9 
500.6 ± 
27.8 
573.2 ± 
57.1 
489.6 ± 
46.3 
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